OBSTETRICAL SONOGRAPHY

Name of Patient : Amrita Limbu **Date :** 30.09.2023

A live intrauterine fetus is seen in a gestational sac.

CRL measures : 86.4mm, Corresponding to 14weeks 4days.

Fetal heart rate : 162bpm

Placenta on the posterior wall

Nuchal translucency : 2.4mm

Cervical length : 39.5mm

Both ovaries appears normal

Signature

SagePath
Excellence In Health Care

Consent Form

☐ **Non-Invasive Prenatal Test - NIPT**

☐ **Non-Invasive Prenatal Test - NIPT Microdeletion**

(To be filled in by patient) Vial ID:

Patient	Name	Ameita Limbu		Date of Birth (DD/MM/YYYY)	31/12/1984	ID/Passport No	7665 9142 3363
	Address	Nauholia				Contact number	9854105208
	Weight	64 kg	Blood Type	(A+ve) Positive	Inherited Disease ☑NO ☐ YES		
Pregnancy	Gestation Period 14 Weeks				Pregnancy type ☑Singleton ☐ Multiple		
	Past history of Gestation Abnormality ☑No ☐ Yes						

(To be filled in by Clinical/Medical Institution)

Pregnancy profile	Doctor	Mukesh Fogla	Undergoing IVF ☑No ☐Yes (Number of embryos: Implantation____Blighted ovum____Fetal reduction____)				
	Down Syndrome test	☐ none so far ☐ NT_____Notes:					
		T21_____T18_____T13 _____					
Sample info	Medical Institution	Ultracare Diagnostic Centre	Contact number	8453036348	Blood taken by	Himadree Gogoi	Blood quantity 10 mL
	Blood collection date	30/09/23	Blood pick up date			30/09/23	
Collection agent			Condition of blood	Good	Blood ID	Ameita Limbu	

Purpose and method of the test

The Firstvue NIPT (Non Invasive Prenatal Testing) was developed by PathCare Labs. This test is designed to screen for Trisomy 13 (Patau syndrome), Trisomy 18 (Edwards syndrome) and Trisomy 21 (Down syndrome). The test is performed by first collecting a 10 ml blood sample from an expecting mother at least 10 weeks into the pregnancy. Cell-free fetal DNA is then extracted from the blood sample for subsequent DNA sequencing. Through innovative next-generation DNA sequencing technology, and specialized bioinformatics analysis, this test platform has a detection rate of over 99.9% for the above-mentioned genetic anomalies.

Recommended use of this test:

The Firstvue NIPT should be considered after close consultation with your physicians and if possible a genetic counselor.

The test is recommended in cases where:

1. Patients are concerned about the risk of invasive prenatal diagnosis; and/or
2. Patients have unusual ultrasonography findings which suggest chromosome abnormality; and/or
3. Patients are of advanced maternal age and or have a higher risk of their fetus being diagnosed with Down syndrome.

Test Results:

The test report will indicate a Positive (aneuploidy detected) or Negative (aneuploidy not detected) result for each of the conditions listed above.

In very few cases, the test does not report any results. In these circumstances, PathCare Labs will provide a free re-test. If the re-test produces no results, the patient will be refunded the initial cost of the test.

this NIPT serve as a reference for your physicians to suggest further treatment.

The accuracy and quality of the test may be adversely affected by improper blood sample collection, storage and transportation accuracy and quality of the test may also be adversely affected by samples taken from patients that have received medical trea including allogeneic blood transfusion, transplant operations, and stem cell therapy within 30 days of sample collection.

This test is not suitable for:

-Patients with dizygotic multiple gestation.

-Patients with diagnostic results that have revealed chromosomal aneuploidy.

-Patients who have previously accepted blood transfusions from other than themselves, or have undergonetransplantation surgery, stem cell therapy or egg donation.

-Patients at less than 10 weeks gestation.

-Patients who have tested positive for HIV and/or Hepatitis B C.

Limitations of the test:

Chromosomal abnormalities such as chromosomal rearrangements, duplications, copy number variations, balanced transloca inversions, imbalanced translocations, uniparental disomy, mosaicism etc., are not within the scope of detection. Therefore, th does not guarantee that a fetus will be free from a genetic disease. NIPT Microdeletion test isa risk assessment test only and do guarantee that a fetus will be free from genetic microdeletion.

Informed consent:

If the NIPT test result is high risk, PathCare will reimburse the cost of further confirmatory diagnostic tests including amniocentesis and chromosome fluorescence in situ hybridization (FISH).

Privacy and confidentiality: